Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Evenity. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 1 application for Romosozumab-aqqg (sold as Evenity), first approved Apr 9, 2019, with 0 new uses approved and 1 published complete response letter.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Evenity
$36.9M for 18,535 prescriptions, +31% on 2024
Where Medicare prescribes it
37,430 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Hawaii 7.0×, California 3.5×, New York 2.0×
Least
Ohio 0.3×, Illinois 0.5×, North Carolina 0.5×
How its trials ended
33 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 9 whose ending is known, 89% met their primary endpoint, 0% missed it and 11% stopped early.
Ongoing1442%OngoingCount14Share42%
Completed, result not reported927%Completed, result not reportedCount9Share27%
Met its primary endpoint824%Met its primary endpointCount8Share24%
Stopped: other or unclear13%Stopped: other or unclearCount1Share3%
Status unknown13%Status unknownCount1Share3%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Fall (174), Arthralgia (129), Headache (108), Hospitalisation (97), Death (91), Injection site pain (88), Femur fracture (83), Off label use (80), Fatigue (78), Pain (69)
First approved in Japan 3 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Evenity, new ingredientA drug with a new active ingredient indicated for the treatment of osteoporosis with a high risk of fracture. · Amgen Astellas BioPharma K.K. · Jan 8, 2019 · Review report
Approvals in Canada (Health Canada)
First approved in Canada 2 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA